By Nancy Lapid April 17 (Reuters) - Researchers have developed a modified version of the CRISPR gene-editing tool that in early laboratory experiments suggests it may have the potential to “silence” ...

Researchers at Oregon Health & Science University have uncovered a key reason why immunotherapy has largely failed in ...

This roundup highlights the latest robotics innovations aimed at improving throughput, simplifying deployment and helping ...

The data to be presented show that Geminii's bioelectronic therapy slowed tumor growth, extended survival, and enhanced the activity of chemoradiation in multiple preclinical NSCLC models without ...

An innovative gene-editing strategy could establish a new way for the body to manufacture therapeutic proteins—including ...

Researchers showed that an experimental therapy indirectly converted suppressive immune cells into tumor-fighting cells. This ...

New study reveals metabolic remodeling as an early event in diastolic dysfunction Restrictive cardiomyopathy (RCM) caused by ...

A burgeoning field is launching its first clinical trial to find out whether dialing back cell development can safely refresh ...

Scientists at Life Biosciences are preparing to begin testing partial reprogramming in people. It will mark the first time ...

One of the most studied lifespan-extending drugs in animals has just failed its test on humans in a 13-week clinical trial co ...

Being able to rapidly reprogram Angry Kitten pods remotely based on the real-time threat environment would be hugely valuable ...